In fact, the market supply of influenza vaccine this year has greatly increased compared with previous years. "So far this year, more than 30 million people have been distributed, and it is estimated that it will reach 50 million people before the arrival of the flu season next month." Zhang Hui, vice president of China Institute of Food and Drug Control, said.
At the same time, according to the statistics on the batch issuance of biological products issued by the US Food and Drug Administration in China, as of September 8, the total batch issuance of influenza vaccines in China has exceeded 654.38 05.87 million doses, including 8,942,700 doses of trivalent influenza vaccine, 4,065,438 doses of tetravalent influenza vaccine and 2,965,438 doses of freeze-dried live attenuated influenza vaccine.
"It seems that a needle is hard to find. In fact, many vaccines are unattended, resulting in a rejection rate of influenza vaccines in China as high as 20%. " Vaccine expert Tao Lina said in an interview.
According to the Vaccine Management Law and related regulations, the holder of vaccine marketing license shall supply vaccines to the disease prevention and control institutions in accordance with the procurement contract, and then the disease prevention and control institutions shall supply vaccines to the inoculation units in accordance with the regulations. Units and individuals other than disease prevention and control institutions shall not supply vaccines to vaccination units, and vaccination units shall not receive vaccines.
"This means that enterprises can't directly supply to vaccination units. There is a contradiction between the supply and demand of influenza vaccines in domestic provinces and cities, and it is impossible to transfer goods from other places, resulting in inexhaustible vaccines in some places and no seedlings in some places." Shi Lichen, founder of Beijing Chen Ding Management Consulting Co., Ltd. said.
Extended data
Get out of the strange circle of "vaccines are in short supply and scrapped at the same time";
Earlier reports pointed out that due to the impact of the longevity biological vaccine incident, the stricter supervision of the vaccine law led to a decline in the speed of batch issuance. However, Shi Lichen said that the government still needs to liberalize batch issuance as much as possible, allowing enterprises to publicize in a reasonable way within a certain range, so that more people can understand the role of influenza vaccine.
Tao Lina suggested that the government should increase procurement efforts, allow more people to vaccinate for free, include vaccines in the scope of public vaccination for specific groups, enlarge the total demand for influenza vaccines, strengthen the stability of supply for enterprises, and establish a dialogue platform and linkage mechanism between supply and demand, so that production enterprises have the confidence and motivation to produce influenza vaccines that people need.
World Wide Web-Influenza vaccine is "hard to find with one needle": queuing to make an appointment to fight for character, and scalpers increase their prices by nearly three times.